DOI: 10.12890/2025_005061

Exploring ANCA Pathogenicity in Ulcerative Colitis: A Case Report Highlighting the Risk of Progression to ANCA-Associated Vasculitis

Authors

  • Abir Hamid Internal Medicine Department, Hôpital Erasme, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Frederic Vandergheynst Internal Medicine Department, Hôpital Erasme, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Maxime Ilzkovitz Internal Medicine Department, Hôpital Erasme, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium

abir.hamid@ulb.be

Keywords

Anti-PR3, ANCA, ANCA-associated vasculitis, ulcerative colitis, diffuse alveolar haemorrhage

Abstract

This case report addresses the association between ulcerative colitis and ANCA vasculitis-associated alveolar hemorrhage. A 20-year-old African woman with a history of ulcerative colitis with high PR3-ANCAs titer presented to the emergency department for chest pain, dyspnea, and hemoptysis in January 2022. A thoracic CT scan and bronchoalveolar lavage were compatible with alveolar hemorrhage. This case emphasizes the pathogenic kinetics of high ANCA titer in ulcerative colitis.

View the entire article

Downloads

References

  1. Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Primers 2020;6:71.
  2. Olson SW, Owshalimpur D, Yuan CM, Arbogast C, Baker TP, Oliver D, et al. Relation between Asymptomatic Proteinase 3 Antibodies and Future Granulomatosis with Polyangiitis. Clin J Am Soc Nephrol 2013;8:1312–1318.
  3. Bornstein G, Ben-Zvi I, Furie N, Grossman C. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis. Int J Rheum Dis 2019;22:940–945.
  4. Folci M, Ramponi G, Solitano V, Brunetta E. Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis. Clin Rev Allergy Immunol 2022;63:107–123.
  5. Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012;18:1340–1355.
  6. Arias-Loste MT, Bonilla G, Moraleja I, Mahler M, Mieses MA, Castro B, et al. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 2013;45:109–116.
  7. Imakiire S, Takedatsu H, Mitsuyama K, Sakisaka H, Tsuruta K, Morita M, et al. Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis. Gut Liver 2022;16:92–100.
  8. Humbert S, Guilpain P, Puéchal X, Terrier B, Rivière S, Mahr A, et al. Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group. Rheumatology (Oxford) 2015;54:1970-1975.
  9. Mumtaz S, Valecha J, Hochwald A, Berianu F, Majithia V, Abril A. Investigating the concomitance of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides and inflammatory bowel disease (IBD). Semin Arthritis Rheum 2024;66:152452.
  10. Sy A, Khalidi N, Dehghan N, Barra L, Carette S, Cuthbertson D, et al. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Semin Arthritis Rheum 2016;45:475–482.
  11. Long D, Mao C, Xu Y, Zhu Y. The emerging role of neutrophil extracellular traps in ulcerative colitis. Front Immunol 2024;15:1425251.
  12. Forrest JA, Shearman DJ. Pulmonary vasculitis and ulcerative colitis. Am J Dig Dis 1975;20:482–486.
  13. dos Santos CE, Dal Pizzol VI, Aragao SC, Rachid Filho A, Marques FM. c-ANCA associated vasculitis in patients with ulcerative colitis: case report. Rev Bras Reumatol 2013;53:441–443.
  14. Vesel HT, Eithz C. Pulmonary vasculitis as an extraintestinal manifestation in ulcerative coliltis. Ugeskr Laeger 1998;160:2116–2117.
  15. Bar-Dayan Y, Ben-Zikrie S, Fraser G, Ben-Ari Z, Braun M, Kremer MR, et al. Pulmonary alveolar hemorrhage in a patient with ulcerative colitis and primary sclerosing cholangitis. Isr Med Assoc J 2002;4:464–465.
  16. de Prost N, Parrot A, Cuquemelle E, Picard C, Antoine M, Fleury-Feith J, et al. Diffuse alveolar hemorrhage in immunocompetent patients: etiologies and prognosis revisited. Respir Med 2012;106:1021–1032.
  17. Mirouse A, Parrot A, Audigier V, Demoule A, Mayaux J, Geri G, et al. Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study. Crit Care 2020;24:231.
  18. Aoyama Y, Inaba T, Takahashi S, Yasuhara H, Hiraoka S, Morimoto T, et al. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol 2021;21:325.
  19. Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-alpha Agents in Patients with Ulcerative Colitis. Inflamm Intest Dis 2021;6:117–122.
  20. Kemna MJ, Schlumberger W, van Paassen P, Dahnrich C, Damoiseaux JGMC, Cohen Tervaert JW. The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up. Clin Exp Immunol 2016;185:141–147.
Chest computed tomography scan: bilateral perihilar ground-glass opacities with condensations in the right lower lobe without any sign of pulmonary embolism

Published

2025-05-05

Issue

Vol. 12 No. 5 (2025)

Categories

How to Cite

1.
Hamid A, Vandergheynst F, Ilzkovitz M. Exploring ANCA Pathogenicity in Ulcerative Colitis: A Case Report Highlighting the Risk of Progression to ANCA-Associated Vasculitis. EJCRIM [Internet]. 2025 May 5 [cited 2026 Nov. 3];12(5). Available from: https://ejcrim.com/index.php/ejcrim/article/view/5061

Most read articles by the same author(s)